Abstract:The development of chimeric antigen receptor (CAR) T cells enables us to leverage the potency of T cells, redirecting them against tumour cells and reshaping the treatment algorithms for lymphoid malignancies. CAR T cells have proven capable of inducing complete remission in many patients, and even cure a subset of them. Ongoing research seeks to deepen our understanding of the factors influencing their efficacy to enhance the next generation of CAR T‐cell products and refine therapeutic approaches. This review synthesizes key results from clinical trials, insights from the correlative studies and current research endeavours, aiming to translate those lessons into practice. Summary Autologous chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of lymphoid malignancies, leading to the approval of CD19‐CAR T cells for B‐cell lymphomas and acute leukaemia, and more recently, B‐cell maturation antigen‐CAR T cells for multiple myeloma. The long‐term follow‐up of patients treated in the early clinical trials demonstrates the possibility for long‐term remission, suggesting a cure. This is associated with a low incidence of significant long‐term side effects and a rapid improvement in the quality of life for responders. In contrast, other types of immunotherapies require prolonged treatments or carry the risk of long‐term side effects impairing the quality of life. Despite impressive results, some patients still experience treatment failure or ultimately relapse, underscoring the imperative to improve CAR T‐cell therapies and gain a better understanding of their determinants of efficacy to maximize positive outcomes. While the next‐generation of CAR T cells will undoubtingly be more potent, there are already opportunities for optimization when utilizing the currently available CAR T cells. This review article aims to summarize the current evidence from clinical, translational and fundamental research, providing clinicians with insights to enhance their understanding and use of CAR T cells.

Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies

CAR T-cell immunotherapy of B-cell malignancy: the story so far

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Advances in chimeric antigen receptor T cell therapy for treatment of hematological malignancies

CAR T-cell immunotherapy: The path from the by-road to the freeway?

CAR T‐Cell Therapy in Hematologic Malignancies: A Voyage in Progress

Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Long-term outcomes following CAR T cell therapy: what we know so far

Driving CAR T-cells forward

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Chimeric antigen receptor T-cell therapies for lymphoma

CAR T‐cell therapy: Full speed ahead

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes